FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.6  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely bendamustine hydrochloride 25 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely aminolevulinic acid hydrochloride (as 5-aminolevulinic acid) 30 milligram/1 milliliter conventional release oral solution (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing 5-aminolevulinic acid in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only 5-aminolevulinic acid in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab 60 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely hydroxycarbamide 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely triptorelin (as triptorelin pamoate) 11.25 milligram/1 vial powder for conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carfilzomib 60 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carfilzomib 10 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carfilzomib 30 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 60 milligram/1 milliliter conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 25 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely vinorelbine (as vinorelbine tartrate) 10 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely arsenic trioxide 1 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely arsenic trioxide 2 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely brentuximab vedotin 50 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cladribine 1 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely fluorouracil (as fluorouracil sodium) 50 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ipilimumab 5 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely irinotecan hydrochloride trihydrate 20 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab emtansine 100 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab emtansine 160 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rituximab 10 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only alemtuzumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing alemtuzumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only clofarabine in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing clofarabine in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only mitoxantrone in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing mitoxantrone in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely mitoxantrone (as mitoxantrone hydrochloride) 2 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely alemtuzumab 10 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely clofarabine 1 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacarbazine (as dacarbazine citrate) 1 gram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacarbazine (as dacarbazine citrate) 500 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely dacarbazine (as dacarbazine citrate) 200 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely decitabine 50 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely obinutuzumab 25 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely gemcitabine (as gemcitabine hydrochloride) 40 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cetuximab 5 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely fludarabine phosphate 25 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely gemcitabine (as gemcitabine hydrochloride) 38 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely gemcitabine (as gemcitabine hydrochloride) 100 milligram/1 milliliter conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely decitabine 50 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely paclitaxel (as albumin bound paclitaxel) 100 milligram/1 vial powder for conventional release dispersion for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely paclitaxel (as albumin bound paclitaxel) 250 milligram/1 vial powder for conventional release dispersion for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely daratumumab 120 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely azacitidine 100 milligram/1 vial powder for conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carmustine 100 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carmustine 100 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely fluorouracil (as fluorouracil sodium) 25 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1a 44 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely interferon beta-1a 88 microgram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ofatumumab 50 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely inotuzumab ozogamicin 1 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ifosfamide 1 gram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ifosfamide 2 gram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely methotrexate (as methotrexate sodium) 50 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely gemtuzumab ozogamicin 5 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely gemtuzumab ozogamicin 5 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely melphalan (as melphalan hydrochloride) 50 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely melphalan (as melphalan hydrochloride) 50 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 3.75 milligram/1 syringe powder for conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 7.5 milligram/1 syringe powder for conventional release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 45 milligram/1 syringe powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 11.25 milligram/1 syringe powder for prolonged-release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely leuprorelin acetate 30 milligram/1 syringe powder for prolonged-release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cladribine 2 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely topotecan (as topotecan hydrochloride) 1 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely topotecan (as topotecan hydrochloride) 1 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely topotecan (as topotecan hydrochloride) 4 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely topotecan (as topotecan hydrochloride) 4 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely thiotepa 15 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely thiotepa 15 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely thiotepa 100 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely thiotepa 400 milligram/1 bag powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tasonermin 1 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tasonermin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only tasonermin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely triptorelin (as triptorelin pamoate) 22.5 milligram/1 vial powder for prolonged-release suspension for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trabectedin 1 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trabectedin 250 microgram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab 420 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab 60 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab deruxtecan 100 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trastuzumab 60 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemetrexed (as pemetrexed disodium) 100 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemetrexed (as pemetrexed disodium) 500 milligram/1 vial powder for conventional release solution for infusion (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely hydroxycarbamide 100 milligram/1 milliliter conventional release oral solution (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely larotrectinib (as larotrectinib sulfate) 20 milligram/1 milliliter conventional release oral solution (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Azacitidine 150mg powder for suspension for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Azacitidine 300mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 60mg powder for solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Azacitidine 200mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Dasatinib 15.8mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Dasatinib 79mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Nivolumab 120mg/12ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Dasatinib 110.6mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Dasatinib 63.2mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 16 of 26 Next End

This concept is not in any reference sets

Back to Start